These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 16455894

  • 1. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
    Pivert A, Payan C, Morand P, Fafi-Kremer S, Deshayes J, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F.
    J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Barreiro P, Romero M, Labarga P, Guardiola JM, Garcia-Samaniego J, Soriano V.
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [Abstract] [Full Text] [Related]

  • 4. The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.
    Pradat P, Maynard M, Buti M, Berthillon P, Picchio G, Tillmann HL, Wiegand J, Voirin N, Manns MP, Esteban JI, Martinot M, Marcellin P, Trepo C.
    J Med Virol; 2004 Jul; 73(3):392-6. PubMed ID: 15170634
    [Abstract] [Full Text] [Related]

  • 5. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
    Payan C, Pivert A, Morand P, Fafi-Kremer S, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F, ANRS HC02 RIBAVIC study team.
    Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.
    J Acquir Immune Defic Syndr; 2007 Feb 01; 44(2):174-8. PubMed ID: 17106276
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V, Núñez M, Camino N, Maida I, Barreiro P, Romero M, Martin-Carbonero L, Garcia-Samaniego J, González-Lahoz J.
    Antivir Ther; 2004 Aug 01; 9(4):505-9. PubMed ID: 15456081
    [Abstract] [Full Text] [Related]

  • 9. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA, Valera-Bestard B, Arizcorreta-Yarza A, González-Serrano M, Torre-Cisneros J, Santos I, Vergara S, Gutiérrez-Valencia A, Girón-González JA, Macías J, López-Cortés LF, Pineda JA.
    Antivir Ther; 2007 Aug 01; 12(4):523-9. PubMed ID: 17668561
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F, Veillon P, Fouchard-Hubert I, Loustaud-Ratti V, Abergel A, Silvain C, Rifflet H, Blanchi A, Causse X, Bacq Y, Payan C, Fontevraud Study Group.
    J Hepatol; 2003 Nov 01; 39(5):826-33. PubMed ID: 14568267
    [Abstract] [Full Text] [Related]

  • 13. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J.
    J Antimicrob Chemother; 2007 Dec 01; 60(6):1347-54. PubMed ID: 17938129
    [Abstract] [Full Text] [Related]

  • 14. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group.
    Antivir Ther; 2005 Dec 01; 10(2):309-17. PubMed ID: 15865225
    [Abstract] [Full Text] [Related]

  • 15. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 16. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.
    Tedder RS, Tuke P, Wallis N, Wright M, Nicholson L, Grant PR.
    J Viral Hepat; 2013 Jan 02; 20(1):65-71. PubMed ID: 23231086
    [Abstract] [Full Text] [Related]

  • 17. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
    Sasase N, Kim SR, Kim KI, Taniguchi M, Imoto S, Mita K, Hotta H, Shouji I, El-Shamy A, Kawada N, Kudo M, Hayashi Y.
    Intervirology; 2008 Jan 02; 51 Suppl 1():70-5. PubMed ID: 18544951
    [Abstract] [Full Text] [Related]

  • 18. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team.
    JAMA; 2004 Dec 15; 292(23):2839-48. PubMed ID: 15598915
    [Abstract] [Full Text] [Related]

  • 19. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C, Solà R, Alvarez NP, Moltó J, Sánchez M, Zamora AM, Ornelas A, Laguno M, González J, von Wichmann MÁ, Téllez MJ, Paredes R, Clotet B, CORAL-2 study group.
    Antivir Ther; 2011 Dec 15; 16(6):833-41. PubMed ID: 21900715
    [Abstract] [Full Text] [Related]

  • 20. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
    Hopkins S, Lambourne J, Farrell G, McCullagh L, Hennessy M, Clarke S, Mulcahy F, Bergin C.
    HIV Med; 2006 May 15; 7(4):248-54. PubMed ID: 16630037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.